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BACKGROUND: Steroid-refractory acute graft-versus-
host disease (aGVHD) is a serious complication after
hematopoietic stem cell transplantation. The long-term
outcome of the patients is poor. Various
immunosuppressive agents have been proposed as the
second-line therapy but none of them has turned out
more effective than the others. Extracorporeal
photopheresis (ECP) is a treatment option that does not
predispose the patients to severe side effects of the
immunosuppressive drugs.
STUDY DESIGN AND METHODS: We analyzed the
treatment results of ECP in 52 patients with steroid-
refractory or steroid-dependent aGVHD. Eighty-one
percent of the patients suffered from a severe, Grade III
or IV, aGVHD. ECP was started alone as the second-line
treatment in 23 patients and in combination with an
immunosuppressive drug in 18 patients. Eleven patients
received ECP as the third-line or later treatment.
RESULTS: A total of 62% of the patients responded,
with 48% achieving complete response. In the patients
with complete or partial response, the probabilities of
survival at 4 years were 54 and 17%, respectively. The
outcome of nonresponders was poor. The 1-year overall
survivals of the patients with ECP as the second-line
treatment either alone or in combination with an
immunosuppressive drug or as the third-line treatment
were 51, 28, and 18%, respectively. In multivariate
analysis, starting ECP no later than 10 days after the
start of the first-line treatment correlated with a good
response and a consequent survival benefit.
CONCLUSION: Extracorporeal photopheresis is an
effective and well-tolerated treatment that should be
considered as a second-line treatment for aGVHD.
A
cute graft-versus-host disease (aGVHD) is a
potentially fatal complication of allogeneic hema-
topoietic stem cell transplantation (alloHSCT).
The standard first-line treatment is a high-dose
steroid, either methylprednisone or methylprednisolone
(MP; 2-10 mg/kg/daily).1 In approximately 40% to 50% of
the patients with aGVHD, the disorder is steroid refractory.
In these patients, the overall survival (OS) is only 17% at 2
years.2 Several treatments, such as mycophenolate mofetil,
infliximab, antithymocyte globulin (ATG), pentostatin,
alemtuzumab, and mesenchymal stem cells, have been
introduced but none of them has proved more effective
than the others.3,4 Treatment with several immunosuppres-
sive drugs leads to a severe immunosuppression and
increases the risk of fatal complications.
Extracorporeal photopheresis (ECP) is a treatment
modality in which buffy coat cells are separated by centri-
fugation and sensitized with 8-methoxypsoralen.5 The
cells are radiated with ultraviolet A light and returned to
the patient’s circulation. The mode of action of ECP is not
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completely understood. It has been suggested that the
sensitized cells undergo apoptosis and are phagocytized
by antigen-presenting cells, leading to the inhibition of
proinflammatory cytokines, increased production of
anti-inflammatory cytokines, and induction of regulatory
T cells.6,7 ECP modulates dendritic cells, alters cytokine
profile, and normalizes CD41/CD81 lymphocyte popula-
tions.8-11 Gatza and coworkers12 showed in murine mod-
els that the transfer of cells treated with ECP reversed
established GVHD by increasing the numbers of donor
regulatory T cells and by reducing the number of donor
effector lymphocytes.
The beneficial effects of ECP are well documented in
chronic GVHD (cGVHD).13 ECP is, however, not available
in all centers or available only for patients with cGVHD.1
The knowledge of the efficacy of ECP in aGVHD is increas-
ing but the numbers of patients in most publications have
remained small. Five large studies with 128, 72, 59, 57,
and 50 patients have been published.14-18 Two of them
have included only children.15,17 In this study, we present
our single-center experience of ECP in severe aGVHD.
MATERIALS AND METHODS
Patients
During the years 2002 to 2015, a total of 63 adult patients
with steroid-refractory or steroid-dependent aGVHD were
treated with ECP in Helsinki University Hospital. The
data of 52 patients with at least two ECP procedures was
included in the present retrospective analysis. Eight
patients with only one procedure and three patients with
aGVHD after donor leukocyte infusion were excluded.
Clinical and transplant data are shown in Table 1. Twenty-
one patients received an allograft from a sibling, 30
patients received an allograft from an unrelated donor,
and one patient received 2 units of cord blood. Three sib-
ling donors showed one HLA antigen mismatch (two A
and one DPB1) while the other sibling donors were 10 of
10 matches. Twenty-eight allografts from an unrelated
donor were at least 10 of 12 HLA matches and two were
nine of 12 matches. Both cord blood units were five of six
matches.
ECP
ECP procedures were performed with one of two photo-
pheresis systems (UVAR XTS [299 procedures] or Cellex
[74 procedures], both Therakos) according to the manu-
facturer’s guidelines. Both devices are fully automated.
One ECP procedure was regarded as a single treatment.
Venous access was provided either by G17 needles
installed into a cubital vein or by a two-lumen central
venous catheter. Heparin in sterile solution of 0.9% NaCl
was used as an anticoagulant, given at a ratio of 10:1.
Methoxalen (Uvadex, Therakos) was injected to the
collection bag in a dose of 0.017 mL per 1 mL of the aphe-
resis product before photoactivation.
Before each ECP, the hemodynamic status of the
patient had to be stable and a white blood cell count of at
least 1 3 109/L. If necessary, the patients were transfused
with red blood cells or platelets (PLTs) to maintain a
hematocrit level of at least 25% and a PLT count of at least
403 109/L.
ECP procedures were performed twice a week, but
not on consecutive days, with the exception of the first
patient, who was treated on consecutive days. ECPs were
continued twice a week until the maximum response.
Maintenance ECPs were not given.
TABLE 1. Clinical and transplant data of 52 patients
treated with ECP due to aGVHD*
Number of patients 52
Age (years) 50 (21-68)
Sex, male/female 28/24
Disease
AML 11
ALL 7
MDS 7
NHL 7
CML 6
MM 6
MF 5
CLL 2
T-PLL 1
Donor
Related/unrelated/double cord blood 21/30/1
Female donor/male recipient 12 (43)
Stem cell source
Peripheral blood 41 (79)
Marrow 10 (19)
Double cord blood 1 (2)
ABO blood group difference
Identical/minor incompatibility/
major incompatibility
30/11/11
Conditioning
Myeloablative (18 CyTBI, 7 BuCy,
14 treosulfan 42 g/m2)
39 (75)
Reduced-intensity conditioning 13 (25)
GVHD prophylaxis
CsA plus Mtx 35 (67)
CsA plus Mtx plus MP 9 (17)
CsA plus mycophenolate mofetil 8 (15)
Pretransplant ATG 22 (42)
Acute GVHD
Grade I 3 (6)
Grade II 7 (14)
Grade III 34 (65)
Grade IV 8 (15)
One-organ involvement 30 (58)
Two-organ involvement 21 (40)
Three-organ involvement 1 (2)
* Data are reported as number, median (range), or number (%).
AML5acute myeloid leukemia; ALL5acute lymphoblastic
leukemia; Bu5busulfan; CLL5 chronic lymphocytic leukemia;
CML5 chronic myeloid leukemia; CsA5 cyclosporine A;
Cy5 cyclophosphamide; MF5myelofibrosis; MDS5myelodys-
plastic syndrome; MM5multiple myeloma; Mtx5methotrexate;
NHL5non-Hodgkin lymphoma; TBI5 total body irradiation;
T-PLL5T-prolymphocytic lymphoma.
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Definitions of aGVHD and evaluation criteria of
response
aGVHD was classified as Grade I to IV according to the
Glucksberg-Seattle scoring system.19 Steroid-refractory
aGVHD was defined as a progression of symptoms within
3 days of the start of the high-dose steroid, no improve-
ment of symptoms despite the treatment with steroids at
a dose of at least 2 mg/kg for 7 days, or incomplete
response after 14 days of 1 to 2 mg/kg/day corticosteroid
therapy.20 Patients who experienced a flare of symptoms
during a steroid taper were regarded as steroid-
dependent.21
Resolution of all aGVHD symptoms in all involved
organs was defined as a complete response (CR) and a sig-
nificant improvement of symptoms as a partial response
(PR).22 No response referred to a stable organ involvement
or a progression of aGVHD.
Statistical analysis
Overall survival was defined as the time from the ECP
onset to the time of death from any cause. Survival
between different response statuses (CR, PR, no
response) was compared by using the Kaplan-Meier
life-table method and an unstratified log-rank test
(p values) and unstratified Cox proportional hazards
model. The analyses related to prognostic factors
(grade, timing of ECP, treatment line, numbers of
involved organs) were performed similarly, with each
prognostic factor analyzed at a time. Based on the
results of the univariate modeling, a multivariate model
was constructed, with the explanatory variables consist-
ing of the prognostic factors that had been proven to be
meaningful in the univariate analysis. Hazard ratios
(HRs) and their 95% confidence intervals (CIs) were
used to quantify the results of the Cox models.
The effect of prognostic factors (grade, timing of ECP,
treatment line, and number of involved organs) on
response status was analyzed with univariate logistic
regression applying Firth’s bias adjustment method sepa-
rately for each factor. Based on the results of the univari-
ate modeling, a multivariate logistic regression analysis
was constructed. Odds ratios (ORs) and their 95% CIs
were used to quantify the results of the logistic regression
analysis. The ORs were constructed for the probability of
reaching a response.
p values of less than 0.05 were considered signifi-
cant, the p values are two-tailed and not adjusted for
multiple testing. Comparisons of categorical variables
between two cohorts were performed using the Fisher
exact test. Statistical analyses were carried out with
computer software (SAS for Windows, Version 9.3, SAS
Institute). Patient data for Kaplan-Meier survival curves
were analyzed with computer software (SPSS, Version
22, IBM Corp.).
RESULTS
Characteristics of aGVHD
Forty-two patients (81%) had a steroid-refractory and 10
patients (19%) a steroid-dependent aGVHD. aGVHD
appeared at a median of 41 days (range, 10-332 days) after
the alloHSCT. Seven patients (13%) were diagnosed as
having aGVHD after Day 1100. In two of them, the late
aGVHD appeared upon immunosuppression withdrawal
on Days1245 and 1332.
Three patients (6%) had Grade I, seven patients (14%)
Grade II, 34 patients (65%) Grade III, and eight patients
(15%) Grade IV aGVHD (Table 1). Neither the source of
the graft nor the conditioning regimen had significant
impact on the risk of severe aGVHD. Seven of 10 (70%)
patients transplanted with a marrow graft and 35 of 41
(85%) patients transplanted with blood stem cells showed
Grade III or IV aGVHD. Of the patients treated with
myeloablative or reduced-intensity conditioning, 85 and
77% presented with Grade III or IV aGVHD, respectively.
At the start of ECP, 30 patients showed one-organ
involvement (20 gut, 10 skin), 21 patients two-organ
involvement (19 skin plus gut, one gut plus liver, one skin
plus liver), and one patient had three-organ involvement
(skin plus gut plus liver). The diagnosis of aGVHD of the
skin was based on clinical evaluation. All gut disorders
were confirmed histologically, whereas the diagnosis of
aGVHD of the liver was based on laboratory tests. All
patients received MP at a dose of 2 mg/kg or more as the
first-line treatment. Cyclosporine A was continued in all
patients.
ECP in the treatment algorithm
Forty-one patients (79%) received ECP as the second-line
treatment. Twenty-three of them were treated with ECP
only, whereas in 18 patients ECP was started concomi-
tantly with an immunosuppressive drug (10 with pentos-
tatin and eight with infliksimab, ATG, or alemtuzumab).
In 11 patients (21%), ECP was the third-line or later
treatment. The previous therapies consisted of pentostatin
(six patients), infliximab (six patients), mycophenolate
mofetil (two patients), ATG (one patient), or an infusion of
mesenchymal stem cells (one patient).
Of the 23 patients treated with ECP alone as the
second-line treatment, 10 patients (43%) had Grade I or II
and 13 patients (57%) Grade III-IV aGVHD. All the other
patients, that is, those treated with combination therapy
as the second-line treatment or those receiving third-line
treatment, presented with Grade III or IV aGVHD.
Extracorporeal photopheresis was started at the
median of 11 days (range, 2-102 days) after the beginning
of the high-dose MP or, in steroid-dependent patients, after
the increase of the MP dose. In 15 patients, ECP was initi-
ated within 7 days of the start of MP or the increase of its
dose. In nine of them, the cause was a rapid progression of
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the symptoms and in the rest a rapid recurrence of the
symptoms after a reduction in MP dose.
The median number of ECPs per patient was six
(range, 2-21). ECPs were well tolerated. One patient expe-
rienced respiratory problems, resulting in the discontinu-
ation of ECPs after the third treatment.
Response of ECP in aGVHD
Thirty-two of 52 patients (62%) responded to the treat-
ment while 20 patients (38%) did not show any response
(Table 2). The first signs of response could be seen after a
median of three ECP procedures (range, two to eight).
Twenty-five patients (48%) achieved CR and seven
patients (14%) PR. The median daily steroid dose at the
start of ECP was 2 mg/kg (range, 0.3-10 mg/kg). In those
patients with a CR or PR, the median dose of MP was
reduced to 0.6 mg/kg at 130 days and to 0.4 mg/kg at
160 days from the start of ECP. Thirteen of 17 surviving
patients have shown cGVHD during the follow-up. At the
time of the present analysis, nine patients receive immu-
nosuppressive treatment for cGVHD.
The grade of aGVHD predicted the probability of
response to ECP (Table 2). Some response was seen in all
10 patients with Grade I or II, in 21 of 34 patients (62%)
with Grade III, and in one of eight patients (13%) with
Grade IV aGVHD. Most patients (eight of 10) with Grade I
or II aGVHD showed CR. In Grades III and IV, CR was
seen less frequently: in Grade III in 15 of 34 patients (44%)
and in Grade IV in one of eight patients (13%; Fig. 1A).
The skin proved the most favorable target for ECP,
with 77% of the patients showing CR. In gut and liver
aGVHD, the CR rates were inferior, 34 and 33%, respec-
tively (Fig. 1B). The number of affected organs did not
predict the probability of response. Fifty-six percent of the
patients with one-organ involvement and 45% of those
with at least two organs involved reached CR.
In univariate analysis, the probability of achieving
response correlated with the earlier start of ECP (OR,
6.040; 95% CI, 1.746-20.888; p < 0.005) and the treatment
line (OR, 10.523; 95% CI, 1.982-55.859; p 5 0.02). When
ECP was started within 10 days of the start of the high-
dose steroid, 16 of 25 patients (64%) obtained CR. Of the
27 patients with delayed start of ECP, only nine (33%)
achieved CR. In the patients suffering from Grade III or IV
aGVHD, an early start of ECP resulted in CR in 12 patients
(57%) while in those with a delayed start, CR was seen in
four patients (19%; p 5 0.02). The majority of those who
received ECP as the second-line treatment showed CR or
PR (Table 3). The overall response rates (ORRs) with ECP
alone in the second line was 83 and 56% for ECP com-
bined with an immunosuppressive drug. In the third line,
the ORR was 27%.
In multivariate analysis, the only significant factor
related to the response rate was the early start of ECP. The
response rate was significantly better if ECP procedures
were initiated within 10 days of the start of a high-dose
steroid in steroid-refractory aGVHD or of an increase in
MP in steroid-dependent aGVHD (OR, 5.274; 95% CI,
1.212-22.943; p 5 0.03). The grade of aGVHD had no
significant impact on the response rate in multivariate
analysis.
Survival
The median follow-up time for all patients was 6 months
(range, 1-156 months) from the start of ECP. Seventeen
patients (33%) were alive after a median follow-up of 31
months (range, 5-156 months) from the ECP onset, while
35 patients had died at a median of 3 months (range, 1-25
months). Fifty-three percent of the patients (17/32) with
any response to ECP were alive, while none of the 20 non-
responding patients survived. The cause of death in all
TABLE 2. Response to ECP according to the grade
of aGVHD and the organ involvement*
Total
number CR PR No response
Number of patients 52 25 (48) 7 (14) 20 (38)
Grade
I 3 2 (67) 1 (33) 0
II 7 7 (100) 0 0
III 34 15 (44) 6 (18) 13 (38)
IV 8 1 (13) 0 7 (87)
Affected organ
Skin 31† 24 (77) 1 (3) 6 (19)
Gut 41‡ 14 (34) 6 (15) 21 (51)
Liver 3 1 (33) 0 2 (67)
One organ 30 17 (56)
Two or more organs 22 10 (45)
* Data are reported as number (%).
† Ten as only involvement.
‡ Twenty as only involvement.
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Fig. 1. (A) CR rates according to severity of aGVHD. (B) CR
response rates according to organ involvement of aGVHD.
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nonresponding patients was aGVHD. In addition, 15 of 32
responders died during a median follow-up of 9 months
(range, 3-28 months), including five patients with PR and
10 with CR. The main cause of death was a transplant-
related complication: an infection, late recurrent aGVHD,
or cGVHD. Two patients, both with CR, had a relapse of
the hematologic malignancy.
In patients with CR or PR, the probabilities of survival
at 4 years from ECP onset were 54 and 17%, respectively
(Fig. 2). The outcome of the patients with no response
was dismal. The 1-year survivals of the patients with ECP
as the second-line treatment alone or in combination
with an immunosuppressive drug or as the third-line
treatment were 51, 28, and 18%, respectively (Fig. 3).
Accordingly, 1-year transplant-related mortalities were 43,
68, and 82% in these groups.
In univariate analysis, the significant prognostic factors
for survival were CR to ECP (HR, 0.08; 95% CI, 0.03-0.19;
p < 0.0001) and the start of ECP within 10 days of the initi-
ation of a high-dose MP (HR, 0.41; 95% CI, 0.21-0.82;
p 5 0.009). The number of involved organs, grade, or ECP
treatment line did not predict survival. In multivariate
analysis, the start of ECP within 10 days was associated
with improved survival (HR, 0.42; 95% CI, 0.20-0.90;
p5 0.009).
DISCUSSION
The results of this analysis of ECP in the treatment of
aGVHD are encouraging. More than half of the patients
(36/52) responded. The prognosis of the patients who
achieved CR was better than the prognosis of those with
only PR or no response. The early start of ECP after the
failure of steroid treatment was associated with a higher
probability of a good response, also in patients with Grade
III or IV aGVHD, translating to a survival benefit.
The CR rate in our study (48%) was somewhat lower
than that in some of the previous publications with adult
patients (52%-91%)14,18,23 but in line with some other
reports, such as that by Perfetti and colleagues24 (52%)
and Hautmann and colleagues21 (30%). A total of 62% of
the present patients showed some response to ECP, and in
the second-line treatment the ORR was 71%, while the CR
rate was 56%. In the largest study with 128 adult patients
with steroid-refractory or steroid-dependent aGVHD,14
TABLE 3. Response to ECP in 52 patients with aGVHD, the number of patients alive at the time of the present
analyses, and the transplant-related mortality (TRM) according to the ECP groups*
ECP Total number
Response
No response Alive TRMAny CR PR
Second-line 41
Alone 23 19 (83) 16 3 4 (17) 10 (43) 11 (48)
In combination† 18 10 (56) 7 3 8 (44) 5 (28) 12 (67)
Third-line 11 3 (27) 2 1 8 (73) 2 (18) 9 (82)
* Data are reported as number (%).
† Pentostatin, infliximab, ATG, or alemtuzumab.
Fig. 2. Survival of patients treated with ECP according to the
treatment response.
Fig. 3. Survival of patients treated with ECP as a second-line
treatment, either alone or in combination with another
immunosuppressive drug or as a third-line treatment.
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the ORR of ECP as the second-line treatment was 77% and
the CR rate was 67%. However, in the study by Das-Gupta
and colleagues,14 the proportion of the patients with
Grade III or IV aGVHD was lower than that in this study
(30% vs. 81%, respectively). In our patient population, in
line with previous reports,14,16,18,23,24 the skin involvement
presented the most favorable target (CR, 77%), whereas
only one-third of our patients with gut or liver involve-
ment showed CR. Greinix and colleagues16 have reported
better results; up to two-thirds of their adult patients with
liver or gut aGVHD achieved CR. The highest CR rates in
gut involvement, up to 75%, have been reported in
children.15,17,25
The differences in response rates may be explained by
differences in patient populations and local practices in
transplant centers. In our study, the proportion of the
patients with severe aGVHD was high, 81%, compared with
many of the other studies in which 20% to 60% of the
patients suffered from Grade III or IV aGVHD.14,16,18,23,24 In
the study by Malagola and colleagues,23 in which the ORR
was as high as 91%, the majority of the patients (80%) pre-
sented with Grade II aGVHD. In addition, the proportion of
the present patients with steroid-refractory aGVHD was
higher (81%) than that in the studies by Greinix and col-
leagues16 (37%) and Malagola and colleagues23 (49%).
Within our patient population, in one-fifth of the cases,
ECP procedures were initiated in the third-line or later,
while most studies have reported efficacy of ECP as a
second-line treatment. Local practices in place at the trans-
plant centers may also have an impact on the differences
in the results. The majority of the reports are based on the
experiences of a single center. Different centers may have
different policies concerning indications, timing, and avail-
ability of ECP, thus leading to variable treatment results.
The prompt start of ECP may be the most crucial
aspect of the treatment of severe aGVHD. In our patients,
the start of ECP within 10 days of the beginning of the
high-dose MP showed significant association with a
response and a survival benefit. In addition, a significant
proportion (57%) of the seriously ill patients with Grade III
or IV aGVHD also responded to the early start of ECPs. In
the study of Perfetti and colleagues,24 the initiation of ECP
within 35 days of the aGVHD diagnosis resulted in higher
response rates. In several studies, the efficacy of ECP has
been shown to be better in patients with a lower-grade
aGVHD.14,16,17,24 Das-Gupta and colleagues14 reported a
better 2-year OS and a lower 2-year nonrelapse mortality in
the patients with lower stages of liver involvement and
lower aGVHD grades. Therefore, an early start of ECP
should be considered before irreversible tissue changes
manifest. The Italian expert groups (SIdEM and GITMO)
have introduced to their guidelines a recommendation of
an early start of ECP in the treatment of aGVHD.26
We know that our study has several limitations due to
its retrospective nature and the long study period. At
present, in many transplant centers, ECP is regarded as
one of the second-line treatment options in steroid-
refractory aGVHD even though its status is not fully estab-
lished.1 Sixteen years ago, when the first of our patients
was treated, ECP was a highly experimental treatment and
mainly seen as a component of a combination therapy. In
our center, the confidence in the benefits of ECP in severe
aGVHD has increased during the study period, which has
resulted in modifications in our practice. During 2002 to
2007, for 75% of the patients, ECP was started in combina-
tion with an immunosuppressive drug, such as ATG,
infliximab, alemtuzumab, or pentostatin. Since 2008, ECP
has not been combined with immunosuppressive drugs
except with pentostatin for the treatment of steroid-
refractory gut aGVHD. Thus, over the past 10 years,
approximately half of the ECPs in our clinic have been
carried out as the only second-line treatment of aGVHD.
The change in the treatment policy is a consequence of
our encouraging results and thus it may have caused a
bias in this study.
Acute GVHD is the most serious treatment-related
complication occurring after alloHSCT. Approximately 30%
to 50% of the patients with aGVHD need a second-line
treatment.27,28 The prognosis of patients with steroid-
refractory Grade III or IV aGVHD is dismal, hampering pro-
spective randomized studies of ECP.29 Approximately 80%
of our patients belonged to the groupwith a poor prognosis.
Various immunosuppressive agents have been proposed as
the second-line therapy4,30 but especially the long-term sur-
vival of the patients with Grade III or IV aGVHD has
improved only a little during the past decades.29,31 Several
lines of immunosuppressive drugs expose patients to severe
side effects such as fatal infections. Therefore, effective ther-
apies that do not predispose patients to infections or other
steroid-related complications (osteoporosis, diabetes, etc.)
are highly desired. On the basis of our experiences, ECP is
an effective and well-tolerated treatment option for patients
also with severe aGVHD.
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